Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Enterprise Value (2016 - 2025)

Acro Biomedical has reported Enterprise Value over the past 10 years, most recently at -$4098.0 for Q4 2025.

  • Quarterly results put Enterprise Value at -$4098.0 for Q4 2025, down 760.92% from a year ago — trailing twelve months through Dec 2025 was -$4098.0 (down 760.92% YoY), and the annual figure for FY2025 was -$4098.0, down 760.92%.
  • Enterprise Value for Q4 2025 was -$4098.0 at Acro Biomedical, up from -$4323.0 in the prior quarter.
  • Over the last five years, Enterprise Value for ACBM hit a ceiling of -$26.0 in Q2 2025 and a floor of -$357668.0 in Q1 2022.
  • Median Enterprise Value over the past 5 years was -$5202.0 (2022), compared with a mean of -$45593.5.
  • Biggest five-year swings in Enterprise Value: crashed 99042.95% in 2021 and later surged 98.73% in 2023.
  • Acro Biomedical's Enterprise Value stood at -$95248.0 in 2021, then surged by 93.86% to -$5852.0 in 2022, then skyrocketed by 93.57% to -$376.0 in 2023, then fell by 26.6% to -$476.0 in 2024, then plummeted by 760.92% to -$4098.0 in 2025.
  • The last three reported values for Enterprise Value were -$4098.0 (Q4 2025), -$4323.0 (Q3 2025), and -$26.0 (Q2 2025) per Business Quant data.